

ASX ANNOUNCEMENT

BENITEC ROADSHOW INVESTOR PRESENTATION

Sydney Australia, 15 March 2014 Benitec Biopharma Limited (ASX: BLT) is pleased to release a copy of the presentation that Dr Peter French, CEO and Managing Director will deliver to investors during March.

The updated presentation:

- Provides additional detail on the recent capital raising undertaken and how funds will be applied to transforming Benitec to a company with multiple clinical assets, and
- Outlines the case for shareholders to approve the second tranche of shares at the upcoming general meeting on 10th April at 11:00am.

For further information, please contact the persons outlined below, or visit the Benitec website at www.benitec.com.

<i>Company</i>	<i>Investor relations</i>
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com	Jane Lowe Buchan Consulting Tel: +61 (2) 9237 2807 Email: jlowe@buchanwe.com.au

About Benitec Biopharma Limited:

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.